Introduction {#S1}
============

Dysregulation of *c-myc* expression through chromosomal translocations was first discovered as a mechanism of tumorigenesis in Burkitt's lymphoma^[@R1]^. Subsequent studies showed derangements of *c-myc*, and its relative *N-myc*, in other malignancies, including lymphomas, neuroblastomas, melanomas, and breast cancer, often through insertional mutagenesis or amplification^[@R1],\ [@R2]^. In multiple myeloma, translocations involving *c-myc* were originally detected in a small proportion of tumors^[@R3]^ and felt to be late events^[@R4]^. More recent studies, however, found *c-myc* rearrangements in almost half of cases, including in precursor states such as smoldering myeloma^[@R5]^. These rearrangements position *c-myc* near genes associated with super-enhancers that drive high levels of c-MYC expression^[@R5],\ [@R6]^, which has been associated with an adverse clinical prognosis in myeloma in at least some studies^[@R6]--[@R9]^, possibly due to a role for c-MYC in drug resistance^[@R10]^. Such data suggest that myeloma patients whose tumors bear *c-myc* aberrations may have high-risk disease for which novel therapies are needed^[@R11]^.

*c-myc* has been considered to be undruggable because of its role in proliferation of normal tissues, and its function through protein-protein interactions^[@R1],\ [@R2]^. Recent studies have identified a number of promising leads, including those targeting chromatin modifications associated with MYC-mediated transcriptional activation. Acetylation on lysine residues of nearby histone proteins is recognized and bound by Bromodomain and extra-terminal (BET) family proteins^[@R1],\ [@R2]^. This supported the development of JQ1, a thieno-triazolo-1,4-diazepine that displaced BRD4 from nuclear chromatin, and induced differentiation and growth arrest in BRD4-dependent tumors^[@R12]^. JQ1 down-regulated transcription of *c-myc* and its downstream targets, and produced potent anti-proliferative effects in myeloma models^[@R13]^. Subsequent studies identified the activity of the BET inhibitors JQ1 and OTX015 in a variety of malignancies, including leukemias, lymphomas, and NUT midline carcinomas^[@R14]^.

Beyond direct BRD4 inhibition, another approach could be to reduce BRD4 levels by promoting its degradation. This can be achieved through protein-targeting chimeric molecules (PROTACs), which combine an E3 ligase recognition sequence with a moiety that targets a protein of interest^[@R15]^. The chimera brings the target to an E3 ligase, catalyzing its ubiquitination and subsequent proteasome-mediated degradation^[@R16]^. Progress in this field was enabled by identification of the E3 ligase Cereblon (CRBN) as the binding partner for thalidomide^[@R17]^ and other immunomodulatory drugs (IMiDs)^[@R18]^. A phthalimide-derived moiety was linked with JQ1 to generate a molecule that directed Cereblon-dependent BET protein degradation (dBET1)^[@R19],\ [@R20]^. In models of human leukemia, dBET1 induced a rapid reduction of BRD4 and c-MYC, and activated apoptosis. Given the role of c-MYC in myeloma biology detailed earlier, this prompted us to test the possibility that BET-targeted PROTACs could be effective against myeloma. We therefore selected ARV-825 and ARV-763 for study, as these have been shown to potently and specifically induce BRD4 ubiquitination and degradation^[@R21]^. In the current report, we present data showing that such PROTACs are active against myeloma, overcome mechanisms of drug resistance, combine synergistically with conventional and novel therapeutics, and show activity *in vivo*.

Materials and Methods {#S2}
=====================

Reagents and cell lines {#S3}
-----------------------

Reagents and myeloma cell lines are detailed in the [Supplementary Materials and Methods](#SD1){ref-type="supplementary-material"}. Myeloma cells alone, or in co-culture with stromal cells^[@R22]^, were cultured as previously described^[@R23]^, and validated through The MD Anderson Cancer Center Characterized Cell Line Core. Drug resistant and p53 mutant counterparts were obtained, derived, and propagated as described previously^[@R24],\ [@R25]^.

Cell viability and apoptosis assays {#S4}
-----------------------------------

These were performed as described in the [Supplementary Materials and Methods](#SD1){ref-type="supplementary-material"}.

Western blotting, RNA techniques, immunohistochemistry, immunofluorescence, and MDR1 efflux {#S5}
-------------------------------------------------------------------------------------------

Please consult the [Supplementary Materials and Methods](#SD1){ref-type="supplementary-material"} for details on these techniques.

Animal modeling {#S6}
---------------

This was performed in NOD.Cg-*Prkdc^scid^ Il2rg^tm1Wjl^*/SzJ (NSG) mice (Jackson Laboratory; Bar Harbor, ME) as detailed in the [Supplementary Materials and Methods](#SD1){ref-type="supplementary-material"} using protocols approved by the MD Anderson Institutional Animal Care and Use Committee.

Genomics and proteomics {#S7}
-----------------------

Gene expression profiling (GEP)^[@R25]^ and reverse-phase protein array analyses (RPPA)^[@R26]^ were performed as described previously, with the latter through the MD Anderson RPPA Core Facility, and analyzed as described in the [Supplementary Materials and Methods](#SD1){ref-type="supplementary-material"}.

Statistical analyses {#S8}
--------------------

Wald's chi-square test^[@R27]^ built in the "ESTIMATE" statement in the PROC GENMOD procedure was used to compare the differences of serum light chains between groups. The transformation of logarithm to the base 2 of light chains was used in the analyses to satisfy the normality assumption of the models. Bonferroni multiplicity adjustment was applied for multiple comparisons. Given that a total of 5 comparisons were conducted of the light chain data, a p-value \<0.01 (0.05/5) was considered statistically significant. ANOVA^[@R27]^ was used for the comparisons of bone volume. Given that a total of 3 comparisons were conducted of bone volume, a p-value \<0.017 (0.05/3) was considered statistically significant. SAS version 9.2 and S-Plus version 8.04 were used to carry out the computations for all analyses.

Results {#S9}
=======

BET-targeting PROTACs suppress proliferation and induce apoptosis {#S10}
-----------------------------------------------------------------

The anti-proliferative activity of the BET-targeting PROTACs ARV-825 and ARV-763 was evaluated in myeloma cell lines with *c-myc* translocations^[@R28]^. ARV-825 combines the BRD4-binding moiety of OTX015 with the CRBN-binding properties of pomalidomide^[@R20]^, while ARV-763 combines OTX015 with sequences that target VHL ([Supplementary Figure 1](#SD2){ref-type="supplementary-material"}). These PROTACs were active in all six lines tested, and decreased their viability in a dose-dependent manner ([Figure 1A](#F1){ref-type="fig"}). Concurrent studies with the direct BET inhibitors JQ1 and OTX015 showed that the PROTACs were in general more potent, with lower median inhibitory concentrations (IC~50~'s). The same was also true, although to a lesser extent, when comparing these PROTACs to dBET1, with the exception of KAS-6/1 cells, where dBET1 demonstrated greater potency. In RPMI 8226 cells, for example, which were relatively resistant to JQ1 and OTX015 even at 10 μM, the PROTACs had an IC~50~ of 92 nM for ARV-825 and 1.52 μM for ARV-763, whereas the IC~50~ of dBET1 was 160 nM. MM1.S cells, which were more sensitive to BET-targeted agents, nonetheless showed an up to 10-fold differential effect, with an IC~50~ of 46.4 nM to JQ1, 59 nM to OTX015, and 84 nM for dBET1, while this was 5.7 and 13.2 nM for ARV-825 and ARV-763, respectively. Cell cycle analysis showed that ARV-825 induced a concentration- and time-dependent increase in G~0~/G~1~ phase cells, while the S-phase population dramatically decreased ([Figure 1B](#F1){ref-type="fig"}; left, middle panels). Consistent with this finding, Cyclin-dependent kinase (CDK) 4 and CDK6 levels decreased with both PROTACs, while CDK inhibitor 1/p21 increased ([Figure 1B](#F1){ref-type="fig"}; right panel). As part of cell cycle analysis, we found an increased proportion of sub-G~0~/G~1~ cells, suggesting the activation of apoptosis (not shown). Therefore, we performed staining with Annexin V, and detected enhanced phosphatidyl-serine externalization on MM1.S cells after exposure to ARV-825 or ARV-763 ([Figure 1C](#F1){ref-type="fig"}; top panels), although, importantly, this was much less pronounced in human peripheral blood monocular cells from healthy donors ([Supplementary Figure 2](#SD2){ref-type="supplementary-material"}). Cell death occurred in association with increased poly-(ADP-ribose) polymerase (PARP) cleavage, and appearance of cleaved Caspases-9 and -3 ([Figure 1C](#F1){ref-type="fig"}; bottom panels).

PROTACs reduce expression of BRD4, and downstream BRD4 targets {#S11}
--------------------------------------------------------------

Since PROTACs were designed to target BRD4 for proteasomal degradation, we evaluated their impact on various BRD4-dependent proteins. MM1.S and RPMI 8226 cells were selected as representatives of strongly and weakly responding models, respectively. Both PROTACs induced a concentration- and time-dependent reduction of BRD4 and c-MYC expression ([Figure 2A](#F2){ref-type="fig"}; top, middle panels), while JQ1 and OTX015 produced a modest increase in BRD4 ([Figure 2A](#F2){ref-type="fig"}; bottom panels). BRD2 and BRD3 expression was also reduced ([Figure 2A](#F2){ref-type="fig"}), although higher drug concentrations and longer exposures were necessary relative to BRD4. An increase in BRD4 levels was observed in cells treated with 1,000 nM PROTACs, probably due to competition for binding to their respective ligases between free and BET-bound PROTAC molecules^[@R20]^. JQ1 and OTX015 reduced c-MYC levels less potently, as concentrations of 1,000 nM were needed to quantitatively eliminate c-MYC expression, while the PROTACs did this at only 100 nM, though ARV-763 was less potent in RPMI 8226 cells. Notably, in MM1.S cells, ARV-825 at 100 nM reduced BRD4 and c-MYC levels by 50% after only 4 hours ([Figure 2B](#F2){ref-type="fig"}; left panel). As expected, reduced BRD4 levels led to decreased abundance of the *c-myc* mRNA ([Figure 2B](#F2){ref-type="fig"}; middle panel). Decreased intranuclear c-MYC staining was also confirmed using immunohistochemistry ([Figure 2C](#F2){ref-type="fig"}) and immunofluorescence ([Supplementary Figure 3](#SD2){ref-type="supplementary-material"}) after 24-hour treatment with ARV-825 and ARV-763. Greater than 90% of untreated cell nuclei stained positive for c-MYC with moderate to strong intensity, while ≤50% of nuclei in drug-treated cells were c-MYC positive, and the magnitude of reduction was concentration-dependent (p\<0.001).

Since *N-myc* expression is influenced by BRD4^[@R29]^, we looked at N-MYC in MM1.S cells, and this was also reduced ([Figure 2B](#F2){ref-type="fig"}; right panel). GATA-binding protein 2 expression may suppress *c-myc* mRNA^[@R30]^, while PIM kinases inhibit c-MYC degradation^[@R31]^, but GATA-2 and PIM-2 levels were themselves decreased ([Figure 2D](#F2){ref-type="fig"}), suggesting that these mechanisms did not contribute to the c-MYC changes. Finally, we looked at the impact of binding of ARV-825 to CRBN, and found that Aiolos and Ikaros levels were decreased, consistent with an activation of the CRBN E3 ligase, as was Interferon regulatory factor (IRF)-4 ([Figure 2D](#F2){ref-type="fig"}). Interestingly, while the VHL-targeting ARV-763 was less potent than ARV-825 in reducing Ikaros, and especially Aiolos levels, it did show some activity in this regard, similar to OTX015 and JQ1.

Antagonistic effects of IMiDs and proteasome inhibitors with PROTACs {#S12}
--------------------------------------------------------------------

ARV-825 contains the pomalidomide Cereblon-binding moiety^[@R20]^, and we therefore considered the possibility that ARV-825 and pomalidomide could be antagonistic. To test this, we exposed MM1.S and RPMI 8226 cells to this PROTAC in the presence of vehicle or pomalidomide. There was no enhanced benefit when pomalidomide was combined with 2 nM ARV-825 compared to pomalidomide alone ([Figure 3A](#F3){ref-type="fig"}; top panels). Indeed, at higher ARV-825 concentrations in MM1.S cells, and with all conditions evaluated in RPMI 8226 cells, the ARV-825/pomalidomide combinations were less active than ARV-825 alone. When the VHL-targeted PROTAC ARV-763 was used, in contrast, antagonistic effects were not seen ([Figure 3A](#F3){ref-type="fig"}; middle panels), presumably because ARV-763 did not compete for the CRBN binding site of pomalidomide. Likewise, no antagonism was seen with OTX015 ([Figure 3A](#F3){ref-type="fig"}; bottom panels) since it does not rely on E3 ubiquitin ligases for its efficacy. To test this further, we analyzed the effect of pomalidomide on the PROTAC-induced degradation of BRD4. As expected, pomalidomide and lenalidomide reversed ARV-825-induced degradation of BRD4 ([Figure 3B](#F3){ref-type="fig"}; upper panels), while they had only a minimal impact on ARV-763. In contrast, the proteasome inhibitors carfilzomib and bortezomib^[@R32]^ antagonized the effects of both PROTACs ([Figure 3B](#F3){ref-type="fig"}; lower panels), demonstrating their reliance on intact proteasome function.

BET-targeted PROTACs suppress Akt/mTOR signaling {#S13}
------------------------------------------------

To further delineate the molecular basis of the anti-myeloma activity of these PROTACs, we performed GEP on MM1.S, U266, and RPMI 8226 cells (Gene expression omnibus accession pending). PROTAC-induced GEP changes were similar to those after treatment with the BET inhibitors ([Supplementary Figure 4](#SD2){ref-type="supplementary-material"}). The most up-regulated genes induced by ARV-825 in the three were histones (data not shown), and similar up-regulation was seen in response to ARV-763 in MM1.S and RPMI 8226 cells, though to a lesser extent in U266 cells. Gene set enrichment analysis (GSEA) performed on the three datasets revealed that *c-myc*-dependent signaling was the most significantly decreased ([Supplementary Figure 5A](#SD2){ref-type="supplementary-material"}). In contrast, a gene set up-regulated by mammalian target of rapamycin (mTOR) activation was one of the most enriched ([Supplementary Figure 5B](#SD2){ref-type="supplementary-material"}). Ingenuity Pathway Analysis (IPA) was then used to identify the five most perturbed gene networks by ARV-825. As expected, *MYC* and *BRD4* were among the most common in MM1.S, RPMI 8226, and U266 cells). The remaining three were Hepatocyte nuclear factor 4 alpha (*HNF4A*), which has been associated with a super-enhancer^[@R33]^, and E2F Transcription Factor 1 (*E2F1*) and *E2F4*, E2F family members which were suppressed by BET inhibition^[@R34]^.

To reveal a broader effect of these PROTACs on cellular signaling networks, we performed RPPA analysis ([Supplementary Figure 6](#SD2){ref-type="supplementary-material"}). BRD4 and c-MYC were reduced by PROTACs in MM1.S and RPMI 8226 cells ([Figure 4](#F4){ref-type="fig"}). Likely due to the role of c-MYC in cell cycle control, expression of proteins involved in cell cycle promotion, including Polo-like kinase 1 (PLK1), Checkpoint kinase 1 (CHEK1), and Cyclins B1 and E1 were also reduced. In contrast, expression of proteins involved in cell cycle inhibition, including p21 and p27, was increased. Interestingly, while the GSEA data identified a signature of mTOR activation, expression and activation of several mTOR pathway intermediates was reduced in both cell lines. Among these was phospho-Ser2481-mTOR, phospho-Thr37/Thr-46-Eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) and phospho-Ser65-4E-BP1, phospho-Thr389-Ribosomal protein S6 kinase beta-1 (p70S6K), both phospho-Ser235- and phospho-Ser236-Ribosomal protein S6 (S6), and both phospho-Ser240- and phospho-Ser244-S6. To further confirm key RPPA findings, formal Western blotting was performed and found, for example, that phospho-Ser-473-Akt, phospho-Thr389-p70S6K, and phospho-Ser65-4E-BP1 expression declined in MM1.S but not RPMI 8226 cells ([Figure 5](#F5){ref-type="fig"}), as had been the case in the RPPAs. Further upstream in the mTOR pathway, phospho-Ser241-3-phosphoinositide-dependent protein kinase 1 (PDK1) and phospho-Tyr458-phosphoinositide 3-kinase (PI3K) expression were also decreased in MM1.S cells. These findings are consistent with prior studies suggesting that BRD4 inhibition downregulates PI3K signaling through decreased BRD4 recruitment to the regulatory domains of Epidermal growth factor and Insulin family receptor tyrosine kinases^[@R35]^.

Since ARV-825 was found to inhibit mTOR signaling, it seemed possible that combinations with agents that targeted this pathway could be of interest. Therefore, we next evaluated ARV-825 with either the mTOR inhibitor everolimus, or the Akt inhibitor afuresertib, which have shown anti-myeloma activity as single agents in phase I studies^[@R36],\ [@R37]^. At virtually all of the concentrations tested, ARV-825 with everolimus or afuresertib showed strong synergy, as indicated by a combination index \<1.0 ([Table 1](#T1){ref-type="table"}). In addition, a high degree of synergy was seen between ARV-825 and dexamethasone, and the BH3 mimetics obatoclax and venetoclax.

PROTACs overcome drug resistance mechanisms {#S14}
-------------------------------------------

BRD4 serves as a regulator for p53 target gene transcription^[@R38]^, and 17p deletion with loss of p53 is a high-risk feature in myeloma associated with drug resistance^[@R11]^. We therefore sought to examine the impact of p53 deletion on the efficacy of these PROTACs using otherwise isogenic MM1.S, H929, and MOLP-8 models with wild-type (WT) or knockout (KO) *TP53* generated using sequence-specific zinc finger nucleases^[@R39]^. ARV-825 was somewhat more potent than ARV-763 in all three lines ([Figure 6A](#F6){ref-type="fig"}; top), consistent with the data in [Figure 1](#F1){ref-type="fig"}. Comparing the KO and WT models, the viability curves for each were virtually overlapping, supporting the possibility that PROTACs work in a p53-independent manner. Cell line models of acquired resistance to conventional drugs, including dexamethasone and doxorubicin, and novel agents, including bortezomib, carfilzomib, lenalidomide, and pomalidomide were then studied. Reductions in viability from PROTACs in dexamethasone-resistant cells occurred at concentrations that were comparable to those in drug-naive cells, and at lower concentrations for bortezomib-resistance ([Figure 6B](#F6){ref-type="fig"}). In lenalidomide- and, to a greater extent, in pomalidomide-resistant cells, cross-resistance was observed with ARV-825, but not with ARV-763. This was not explained by decreased CRBN expression in the IMiD-resistant cell lines ([Figure 6C](#F6){ref-type="fig"}), although, notably, BRD4 expression was unchanged, particularly in the U266 P10R cells with ARV-825 treatment. This suggested impairment of CRBN E3 ubiquitin ligase activity in U266 P10R cells, with possible mechanisms including loss of function mutations in CRBN or CRBN-associated proteins that form the E3 ubiquitin ligase complex^[@R40]^.

Carfilzomib- and doxorubicin-resistant cells showed cross-resistance to both PROTACs, and since P-glycoprotein (Multidrug resistance protein 1 (MDR1)) is a factor in the latter^[@R41]^, we evaluated its expression. Consistent with the possibility of a role for MDR1, it was over-expressed in the carfilzomib- and doxorubicin-resistant cells ([Figure 6D](#F6){ref-type="fig"}, top panel; [Supplementary Figure 7](#SD2){ref-type="supplementary-material"}), but not the parental or bortezomib-resistant cells. Increased efflux and decreased fluorescence of DiCO~2~(3), a highly specific substrate dye for MDR1, was also observed in carfilzomib-resistant and doxorubicin-resistant cells relative to their parental cells ([Figure 6D](#F6){ref-type="fig"}, lower panel). We then treated carfilzomib- and doxorubicin-resistant cells with ARV-825 and verapamil, a known MDR1 inhibitor^[@R41]^. Verapamil alone had no influence on cell viability, but its addition to ARV-825, and *vice versa*, sensitized these cells to the PROTAC ([Figure 6E](#F6){ref-type="fig"}). Verapamil also sensitized carfilzomib- and doxorubicin-resistant cells to OTX015 ([Supplementary Figure 8](#SD2){ref-type="supplementary-material"}), suggesting OTX015 is also an MDR1 substrate.

Finally, MM1.S cells were co-cultured with HS5 stromal cells to mimic the marrow microenvironment. Interestingly, the therapeutic activity of ARV-825 and ARV-763 was enhanced in the presence of stromal cells ([Figure 6F](#F6){ref-type="fig"}), which may be explained by HS5-induced *BRD4* expression in myeloma cells^[@R13]^.

BET-targeted PROTACs are active against primary myeloma cells and *in vivo* {#S15}
---------------------------------------------------------------------------

To determine if these PROTACs could potentially be useful in the clinic, their activity was evaluated against primary plasma cell samples. All five demonstrated a dose-dependent decrease in cellular viability after exposure to both agents ([Figure 7A](#F7){ref-type="fig"}; top panels), with ARV-825 showing greater potency. Annexin V staining supported that this was associated with induction of apoptosis ([Figure 7A](#F7){ref-type="fig"}; bottom panels). Also, reduced BRD4 and c-MYC expression were seen in the two samples for which we had sufficient cells to study by Western blotting ([Figure 7B](#F7){ref-type="fig"}). Finally, we used MM1.S cells to establish a xenograft model of systemic myeloma in NSG mice. ARV-825 dosed intraperitoneally, and starting on day 3 after intravenous MM1.S cell injection, slowed the appearance of human lambda light chains ([Figure 7C](#F7){ref-type="fig"}; left panel). Interestingly, a greater benefit was seen with prolonged dosing, as the differences became more dramatic on days 28 and 36 compared to earlier time points, without any apparent toxicity. Also of note, compared to vehicle-treated mice, ARV-825 helped significantly preserve femur bone volume measured at 30-days post-inoculation (p\<0.023)([Figure 7C](#F7){ref-type="fig"}; right panel)([Supplementary Figure 9](#SD2){ref-type="supplementary-material"}).

Discussion {#S16}
==========

Our studies of these BET-targeted PROTACs showed that they induced a strong anti-proliferative effect, cell cycle arrest at G~0~/G~1~, reduced levels of CDK4 and CDK6, and activated Caspase-mediated apoptosis ([Figure 1](#F1){ref-type="fig"}). At the protein level, they potently and rapidly induced BRD4 degradation and subsequently inhibited expression of c-MYC, as well as other down-stream BRD4 targets, including N-MYC and PIM-2. Interestingly, the CRBN-targeted ARV-825 was more potent in most of these assays than the VHL-targeted agent ARV-763. This could be because the two E3 ligases might be different in their efficiency of ubiquitinating BRD4. Also, ARV-825 contains the pomalidomide moiety, and thus can both promote BET degradation, and act to some extent like an immunomodulatory drug. In the latter guise, it can reduce Aiolos and Ikaros levels, and suppress IRF4 and c-MYC independently of its impact on BRD4^[@R42]^, possibly explaining why it reduces c-MYC to a greater extent than ARV-763. However, we cannot exclude the possibility that other factors, such as the expression levels of CRBN and VHL, or differences in cellular uptake and efflux of the PROTACs, may contribute to this differential effect. Importantly, ARV-825, and to some extent also ARV-763, were more potent than JQ1 or OTX015, confirming prior studies in other models^[@R19],\ [@R20]^, and compared to dBET1, suggesting that these PROTACs could ultimately be more active in the clinic.

PROTACs rely for their activity on the availability of their target E3 ligase, and an intact ubiquitin-proteasome pathway. This was demonstrated by the finding that IMiDs interfered with ARV-825 but not of ARV-763 ([Figure 3](#F3){ref-type="fig"}), while proteasome inhibitors antagonized both in inducing BRD4 degradation. With the goal of designing combinations with optimal clinical activity, one may therefore need to use ARV-763, or agents targeting a non-CRBN E3 ligase, with IMiDs. However, the presence of pomalidomide in ARV-825 could make it a bi-functional chemotherapeutic that would preclude the need for an IMiD. Addition of concurrent proteasome inhibitors may need to be avoided with PROTACs ([Figure 3B](#F3){ref-type="fig"}), though some rational sequence of treatment could possibly be validated given the rapid onset of action of PROTACs.

Genomic studies suggested that BET PROTACs activated the mTOR pathway, but proteomic studies showed that they inhibited mTOR and Akt signaling ([Figure 4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}). This contradiction may indicate a compensatory increase in mTOR transcription in response to inhibition of this pathway. However, the GEP data also showed that expression of Myotubularin-related protein 3 (*MTMR3*), a negative mTOR complex 1 (mTORC1) regulator^[@R43]^, was increased, while that of mTOR-associated protein LST8 homolog (*MLST8*), a required subunit and positive regulator of mTORC1 and mTORC2^[@R44]^, was decreased, supporting the possibility of mTOR inhibition. Moreover, these data are consistent with prior studies showing that BET inhibitors lowered phospho-inositide 3-kinase (PI3K) signaling, and dissociated BRD4 from chromatin at regulatory regions of the Insulin-like growth factor-1 receptor^[@R35]^. Also, there is cross-talk between c-MYC-mediated transcription and the PI3K/Akt pathway through MAD-1^[@R45]^, providing several mechanisms through which PROTACs could exert this effect. mTOR-mediated regulation of metabolism is of increasing interest in myeloma^[@R46]--[@R50]^, and mTOR-mediated 4E-BP1 phosphorylation is required for survival of MYC-dependent hematologic malignancies^[@R51]^. The serine--threonine kinase mTOR can form two multi-protein complexes, mTORC1 and mTORC2. mTORC1 can activate mRNA translation through regulation of p70S6K and 4E-BP1, while mTORC2 can activate Akt through Ser473 phosphorylation^[@R52]^. In turn, the ability of mTORC1 to bind its substrates is regulated by a Proline-rich Akt substrate of 40 kDa (PRAS40) that is phosphorylated by Akt at Ser246^[@R53],\ [@R54]^. RPPA analysis revealed a significant effect of our PROTACs on mTORC1 signaling and downstream RNA translation through decreased phosphorylation of Ribosomal protein S6, a direct p70S6K target. Western blotting confirmed decreased phosphorylation/activation of p70S6K and 4E-BP1 in MM1.S cells, and to a lesser extent in RPMI 8226 cells. In MM1.S cells, RPPA showed decreased Akt phosphorylation at Ser473, and a decrease in Akt-mediated phosphorylation of PRAS40, a negative regulator of substrate binding by mTORC1, suggesting inhibition of mTORC1 binding to its substrates in PROTACs-treated MM1.S cells. In RPMI 8226 cells, the RPPA did not show any effect of our PROTACs on Akt and PRAS40, but the PROTACs decreased levels of phosphorylated Tuberin (TSC2), a negative mTORC1 regulator, consistent with the effect of PROTACs on levels of the PIM-2 kinase that can affect mTORC1 activity through phosphorylation of Tuberin^[@R55]^. Taken together, our data suggest that the effects of BET PROTACs on mTORC1 activity are cell line specific, and that Akt signaling could be a pathway of PROTAC resistance. Indeed, the latter hypothesis is further supported by the finding of synergistic interactions between ARV-825 and the Akt inhibitor afuresertib ([Table 1](#T1){ref-type="table"}). Cell-line specific effects could depend, in part, on the ability of PROTACs to suppress parallel upstream regulators of mTORC1 activity, Akt, and/or PIM-2 in myeloma cells^[@R55]^ by decreasing Akt and PRAS40 phosphorylation, and/or decreasing levels of PIM-2 kinase and subsequent phosphorylation of Tuberin.

BET-targeted PROTACs showed comparable activity in *TP53* WT and KO cell line models, and overcame conventional and novel drug resistance, unless this was mediated by P-glycoprotein ([Figure 6](#F6){ref-type="fig"}). These findings suggest that PROTACs should show activity against high-risk myeloma with deletion of 17p, and in the relapsed and refractory setting, which are both areas of high unmet medical need. However, expression of multi-drug resistance efflux pumps has been described to increase in the latter group^[@R56]^, and may influence patient outcomes to therapies such as bortezomib with pegylated liposomal doxorubicin^[@R57]^. Also, a subpopulation of carfilzomib-resistant myeloma cells has been noted to overexpress NIMA-related kinase 2 (*NEK2*), which can up-regulate MDR-related proteins including MDR1 (P-gp), and this was strongly associated with bortezomib and doxorubicin resistance^[@R58],[@R59]^. Thus, additional studies will be needed to determine if the current PROTACs targeting BET proteins, or PROTACs that could be developed against other key myeloma proteins, such as Myeloid cell leukemia (MCL)-1, may need to be avoided in patients with MDR over-expression.

Finally, pre-clinical studies in primary cells, and an *in vivo* murine model of systemic myeloma, showed encouraging activity of ARV-825 ([Figure 7](#F7){ref-type="fig"}). The BET inhibitor OTX015 has recently completed phase I studies with manageable dose-limiting toxicities, and a dose for phase II testing was identified^[@R60]^. Moreover, three diffuse large B-cell lymphoma (DLBCL) patients achieved durable responses, while six others, including two with DLBCL and four with indolent lymphomas, had evidence of clinical activity. Since the PROTACs appear to have a somewhat comparable mechanism of action but greater potency, similar toxicities, which seem to be predominantly focused on the hematopoietic and gastrointestinal systems, where some of the more proliferative normal tissues are found, would be expected. Careful titration of the dose and selection of the schedule based on pharmacokinetic and pharmacodynamic data will be needed to determine the safety and efficacy of this new, promising class of drugs.
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![Cell cycle arrest and apoptosis induced by BET-specific PROTACs\
(A) Viability data obtained using the WST-1 assay are plotted with respect to concentrations of the CRBN- and VHL-targeted BET PROTACs ARV-825 and ARV-763, respectively, the direct BET inhibitors JQ1 and OTX015, and dBET1 after exposure to each agent for 72 hours. Data were collected in triplicate experiments and the mean ± the standard deviation (SD) were plotted for each point. (B) Left and middle panels: The concentration- and time-dependent effects of ARV-825 on cell cycle distribution were evaluated by flow cytometry after exposure of MM1.S cells to this agent under the indicated conditions. Data shown are representative from duplicate experiments. Right panel: Effects of ARV-825 and ARV-763 on the expression levels of p21, CDK4, and CDK6 were examined by Western blotting of MM1.S cell extracts 24 hours after exposure to the indicated drug concentrations of drugs, with β-actin used as a loading control. (C) Top panels: Induction of apoptosis was studied by Annexin V staining of MM1.S cells exposed to ARV-825 or ARV-763, followed by flow cytometry. Experiments were performed in triplicate and the mean ± SD is shown for the indicated conditions. Bottom panels: Programmed cell death activation was confirmed by preparing lysates of the indicated myeloma cell lines and subjecting them to Western blotting for cleaved PARP, Caspase-3 and -9, and β-actin as a loading control.](nihms931794f1){#F1}

![BET-specific PROTACs induce degradation of BRD4 and c-MYC\
(A) The concentration- and time-dependent effects of ARV-825 (top panels) and ARV-763 (middle panels) on BRD4, c-MYC, BRD2, BRD3, and CRBN protein expression were studied by Western blotting in MM1.S and RPMI 8226 cells, with β-actin as a loading control. Also shown are data from these cell lines exposed for 24 hours to the BRD4 inhibitors JQ1 and OTX015 (bottom panels), with representative panels from one of two independent experiments shown for each. (B) Left panel: A time course experiment with earlier sampling points was performed in MM1.S cells exposed to ARV-825 at 100 nM. Middle panel: *c-myc* mRNA levels were determined by qRT-PCR in MM1.S cells exposed to ARV-825 or ARV-763 at the indicated concentrations for 24-hours. Right panel: N-MYC protein levels in MM1.S cells exposed to ARV-825 or ARV-763 were determined by Western blotting, with β-actin as a loading control. (C) Intranuclear c-MYC staining in MM1.S and RPMI 8226 cells exposed to vehicle, ARV-825, or ARV-763 determined by immunohistochemistry. The corresponding values of the intensity of c-MYC staining (H-score) are represented underneath the photomicrographs. (D) Impact of ARV-825 or ARV-763, and of JQ1 or OTX015, on the expression levels of other proteins of interest in MM1.S and RPMI 8226 cells examined by Western blotting, with β-actin serving as a loading control.](nihms931794f2){#F2}

![Activity of PROTACs may be inhibited by immunomodulatory agents and proteasome inhibitors\
(A) The impact of ARV-825, ARV-763, OTX015, or pomalidomide (POM) alone, or in various combinations, was studied in MM1.S and RPMI 8226 cells under the indicated conditions. Cellular viability was determined after 72 hour experiments as detailed in the legend to [Figure 1A](#F1){ref-type="fig"}. Data were collected from triplicate experiments and the mean ± SD are shown. (B) Expression levels of BRD4 in the presence of vehicle, 100 nM ARV-825, 250 nM ARV-763, or combinations of the PROTACs with either 10 μM POM or lenalidomide (LEN), or either 5 nM carfilzomib (CFZ) or bortezomib (BTZ) for 12 hours.](nihms931794f3){#F3}

![BET-specific PROTACs affect cell cycle regulation and the Akt/mTOR pathway\
The effect of ARV-825 or ARV-763 on the expression levels of proteins are shown from reverse phase protein array (RPPA) analysis ([Supplementary Figure 6](#SD2){ref-type="supplementary-material"}) of MM1.S (top panel) or RPMI 8226 (bottom panel) cells. These were treated with either 100 nM ARV-825 or 250 nM ARV-763 for 24 hours prior to preparation for analysis. Normalized linear values of antibody signal representing levels of BRD4 and c-MYC, and of proteins involved in cell cycle regulation and the Akt/mTOR pathway, are plotted as means ± SD from triplicate experiments.](nihms931794f4){#F4}

![Influence of PROTACs on Akt and mTOR pathway signaling\
The effect of ARV-825 or ARV-763 on the expression levels of key intermediates in the PI3K-Akt-mTOR pathway signaling were probed by Western blotting of MM1.S (left panel) and RPMI 8226 (right panel) cells. These were exposed for 24 hours to the indicated drug concentrations prior to harvesting and preparation of cell lysates for analysis.](nihms931794f5){#F5}

![PROTAC-mediated BRD4 degradation overcomes drug resistance\
(A) Otherwise isogenic MM1.S, H929, and MOLP-8 cell lines with either wild-type (WT) *TP53* or a *TP53* knockout (KO) were generated using sequence-specific zinc-finger nucleases targeting a non-specific sequence, or exon 7 of the *TP53* DNA binding domain^[@R22]^. The anti-proliferative effects of ARV-825 and ARV-763 were then studied with viability assays performed as described earlier after a 72-hour drug exposure. Data were collected from triplicate experiments, which are represented as the mean ± SD for each concentration. (B) MM1.S, RPMI 8226, and U266 cells resistant to bortezomib (BR), carfilzomib (CR), dexamethasone (DexR), doxorubicin (DoxR), lenalidomide (R10R), and pomalidomide (P10R), and their corresponding parental cell lines, were studied to determine if there was cross-resistance to ARV-865, ARV-763, and OTX015 as described in panel A. (C) Western blotting of BRD4 and CRBN expression in MM1.S R10R and U266 P10R cells, and their corresponding parental lines after treatment with ARV-825, ARV-763, and OTX015 for 48 hours. (D) Top panel: Expression of the Multidrug resistance protein 1 (MDR1) was evaluated by Western blotting in the indicated drug-resistant and parental cell lines. Bottom panel: MDR1 efflux activity was assessed using DiCO~2~(3), a highly specific fluorescent substrate dye for MDR1. At 4^0^C, MDR1 is inactive and cells retain DiCO~2~(3) after initial dye loading, while at 37^0^C, MDR1 is active and cells will efflux DiCO~2~(3) and exhibit decreased fluorescence. (E) Carfilzomib- or doxorubicin-resistant RPMI 8226 cells were treated with the indicated concentrations of ARV-825, verapamil, or various combinations of the two. Live cell populations were assessed using the WST-1 proliferation assay after exposure to drugs for 72 hours as described in panel A. (F) MM1.S cells were treated for 48 hours with ARV-825 or ARV-763 in the presence or absence of HS5 stromal cells. Cell viability was assessed using flow cytometry with Annexin V (A5)/TO-PRO-3 (PI) staining in triplicate experiments, which are represented as the mean ± SD for each condition. Treatment with dexamethasone was used as a positive control.](nihms931794f6){#F6}

![Activity of BET PROTACs against primary plasma cells and *in vivo*\
(A) Top: The ability of ARV-825 and ARV-763 to reduce viability in primary cells was evaluated in samples from five patients with relapsed and/or refractory myeloma, which were exposed to the indicated drug concentrations for 48 hours. Bottom: Induction of apoptosis was confirmed by staining of cells from patient 1 with Annexin V, followed by flow cytometric analysis. (B) Western blotting was performed on samples from patients 1 and 2, whose cells were treated with ARV-825 and ARV-763, to evaluate the downstream effects on BRD4 and c-MYC expression after 24 hours. (C) NSG mice injected with MM1.S cells through their tail veins were randomized to receive either vehicle (n=6) or ARV-825 (n=6), the latter at 50 mg/kg daily by intraperitoneal injection, beginning on day 3 after tumor cell inoculation. Left panel: Levels of circulating human lambda light chain immunoglobulins were measured over time in these xenograft-bearing mice using an ELISA. Right panel: Quantitation of micro-computed tomography scans of femoral bones in control, and xenograft-bearing mice treated with vehicle or ARV-825 was performed on day 30 post-inoculation. The mean femoral bone volume ± SD are shown for each treatment group.](nihms931794f7){#F7}

###### 

Combination index analysis to determine the promise of ARV-825 in combinations with other conventional and novel anti-myeloma agents

                                 ARV-825 (nM)                               
  ------------------- ---------- -------------- ------ ------ ------ ------ ------
  **Everolimus**      **nM**                                                
                      **0.1**    1.22           0.70   0.66   0.79   0.75   
                      **0.4**    0.54           0.45   0.51   0.60   0.43   
                      **1.6**    0.59           0.45   0.51   0.59   0.60   
                      **6.4**    0.83           0.60   0.52   0.55   0.53   
  **Dexamethasone**   **μM**                                                
                      **1.25**                  0.19                        
                      **2.5**                          0.25                 
                      **5**                                   0.37          
                      **10**                                         0.65   
                      **20**                                                1.24
  **Afuresertib**     **nM**                                                
                      **20**     0.95           1.09   0.83   0.92          
                      **40**     1.11           0.79   0.64   0.80          
                      **80**     0.68           0.65   0.56   0.76          
                      **160**    0.56           0.39   0.46   0.54          
  **Obatoclax**       **nM**                                                
                      **10**     1.10           1.02   0.76   0.92   0.97   
                      **50**     0.71           0.63   0.56   0.79   0.62   
                      **250**    0.34           0.42   0.52   0.37   0.35   
                      **1250**   0.86           0.77   0.77   0.17   0.29   
  **Venetoclax**      **nM**                                                
                      **10**     1.90           1.3    2.39   2.2           
                      **50**     0.84           0.96   0.43   1.1           
                      **250**    0.59           0.27   1.90   0.9           
                      **1250**   0.16           0.07   0.16   0.23          

###### Key Points

-   Protein-targeting chimeric molecules that induce Bromodomain and extraterminal domain protein degradation are active against myeloma.

-   Their ability to activate apoptosis, overcome chemoresistance, and combine with conventional and novel drugs shows promise for the clinic.
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